Clinical trial
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Opening soon · Phase 3 · 4 countries · Registry ID NCT07794579
Opening soonPhase 3Interventional
What this study is about
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionOverweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Full registry criteria
Inclusion Criteria: * Have an increased waist-to-height ratio of ≥0.5 * Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia) * Have at least one unsuccessful attempt to reduce body weight based on diet and exercise * Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds Exclusion Criteria: * Have type 1 diabetes, type 2 diabetes, or any other type of diabetes * Do not have a stable body weight within 90 days before screening * Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold) * Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening * Have a prior or planned surgical treatment or procedure for obesity * Have hypertension or history of hypertension * Have dyslipidemia or history of dyslipidemia
Treatments and study arms
Orforglipron
Drug
Administered orally
Placebo
Drug
Administered orally
Primary outcomes
Time to Onset of Obesity Related Complications or Class 1 ObesityBaseline to Week 104
Obesity related complications defined as type 2 diabetes, hypertension, or dyslipidemia; Class 1 obesity defined as body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or an equivalent region-specific threshold
Study locations
179 locations were listed when this page was built. The first 40 are shown.
CARDIAMET Investigaciones Médicas🇦🇷 Buenos Aires, Argentina
Study contactContact
Angela Romero ZarantePrincipal Investigator
CEMEDIC🇦🇷 Buenos Aires, Argentina
Study contactContact
Claudio MajulPrincipal Investigator
CIPREC🇦🇷 Buenos Aires, Argentina
Study contactContact
Fernando GuerlloyPrincipal Investigator
CONEXA Investigacion Clinica S.A.🇦🇷 Buenos Aires, Argentina
Study contactContact
María SciosciaPrincipal Investigator
Centro Médico Viamonte🇦🇷 Buenos Aires, Argentina
Study contactContact
Diego AizenbergPrincipal Investigator
Fundación Respirar🇦🇷 Buenos Aires, Argentina
Study contactContact
Marina UhrigPrincipal Investigator
Investigaciones Medicas Imoba Srl🇦🇷 Buenos Aires, Argentina
Study contactContact
Silvia OrioPrincipal Investigator
Instituto Centenario🇦🇷 CABA, Argentina
Study contactContact
SUSANA SALZBERGPrincipal Investigator
IDIM - Instituto de Investigaciones Metabólicas🇦🇷 Ciudad de Buenos Aires, Argentina
Study contactContact
Mariela BazanPrincipal Investigator
Sanatorio Esperanza🇦🇷 Esperanza, Argentina
Study contactContact
Guillermo CursackPrincipal Investigator
Centro Diagnóstico Bioimagenes🇦🇷 Lanus, Argentina
Study contactContact
DIEGO LOWENSTEIN HABERPrincipal Investigator
Centro de Investigaciones Médicas Mar del Plata🇦🇷 Mar del Plata, Argentina
Study contactContact
Andres AlvarisquetaPrincipal Investigator
Instituto de Cardiología Wolff🇦🇷 Mendoza, Argentina
Study contactContact
SEBASTIAN WOLFFPrincipal Investigator
Instituto Especialidades de la Salud Rosario🇦🇷 Rosario, Argentina
Study contactContact
Ana ChiesaPrincipal Investigator
Instituto de Investigaciones Clinicas Rosario🇦🇷 Rosario, Argentina
Study contactContact
Carolina ChacónPrincipal Investigator
Centro de Investigaciones Médicas Tucuman🇦🇷 SAN M. de Tucuman, Argentina
Study contactContact
Dina SalicaPrincipal Investigator
CardioAlem Investigaciones🇦🇷 San Isidro, Argentina
Study contactContact
Jorge AiubPrincipal Investigator
Instituto Médico de Alta Complejidad San Isidro Sa🇦🇷 San Isidro, Argentina
Study contactContact
Maria MontecchiesiPrincipal Investigator
Instituto de Investigaciones Clínicas San Nicolas🇦🇷 San Nicolás de los Arroyos, Argentina
Maria FernandezPrincipal Investigator
Centro de Investigaciones Clinicas del Litoral🇦🇷 Santa Fe, Argentina
Study contactContact
Miguel HominalPrincipal Investigator
The First Affiliated Hospital of Anhui Medical University🇨🇳 Hefei, China
Honglin HuPrincipal Investigator
The First Affiliated Hospital of Henan University of Science &Technology🇨🇳 Luoyang Shi, China
Study contactContact
Hongwei JiangPrincipal Investigator
The Second Affiliated Hospital of Nanjing Medical University🇨🇳 Nanjing, China
Study contactContact
Yibing LuPrincipal Investigator
Ningbo First Hospital🇨🇳 Ningbo, China
Study contactContact
Li LiPrincipal Investigator
The First Hospital of Qinhuangdao🇨🇳 Qinhuangdao Shi, China
Study contactContact
Bowei LiuPrincipal Investigator
Tianjin Medical University Zhu Xianyi Memorial Hospital🇨🇳 Tianjin, China
Liming ChenPrincipal Investigator
EFERTUS healthcare s.r.o.🇨🇿 Brno, Czechia
Study contactContact
Hana MatejovskaPrincipal Investigator
Habrypraktik s.r.o.🇨🇿 Habry, Czechia
Study contactContact
Sarka DrinkovaPrincipal Investigator
CCR Ostrava s.r.o🇨🇿 Ostrava, Czechia
Study contactContact
Jozef DodulikPrincipal Investigator
Milan Kvapil s.r.o., Diabetologicka ambulance🇨🇿 Prague, Czechia
Study contactContact
Dagmar BartaskovaPrincipal Investigator
MUDr. Barbora Diepoltova🇨🇿 Praha 9 - Klanovice, Czechia
Study contactContact
Barbora DiepoltovaPrincipal Investigator
MUDr. Alena Vachova🇨🇿 České Budějovice, Czechia
Study contactContact
Alena VachovaPrincipal Investigator
FutureMeds GmbH🇩🇪 Berlin, Germany
Study contactContact
Saskia KerschischnikPrincipal Investigator
Siteworks GmbH - Bochum🇩🇪 Bochum, Germany
Study contactContact
Annemone KoechelPrincipal Investigator